Prognostic value of thymidine phosphorylase immunostaining in patients with uterine cervical cancer treated concurrently with doxifluridine, radiotherapy and immunotherapy

Oncology Reports

Volumn 8, Issue 2, 2001, Pages 239-244

  Sato, Shinji ^a  

^a TOHOKU UNIVERSITY   (Japan)

Author keywords

Immunohistochcmistry; Prognosis; Thymidine phosphorylasc; Uterine cervical cancer

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; DOXIFLURIDINE; FLOXURIDINE; IMMUNOLOGICAL ADJUVANT; SCHIZOPHYLLAN; THYMIDINE PHOSPHORYLASE; TUMOR MARKER;

ARTICLE; CANCER STAGING; FEMALE; HUMAN; IMMUNOTHERAPY; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; STROMA CELL; SURVIVAL RATE; TIME; UTERUS CANCER;

ADJUVANTS, IMMUNOLOGIC; ANTIMETABOLITES, ANTINEOPLASTIC; COMBINED MODALITY THERAPY; FEMALE; FLOXURIDINE; HUMANS; IMMUNOTHERAPY; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SIZOFIRAN; STROMAL CELLS; SURVIVAL RATE; THYMIDINE PHOSPHORYLASE; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; UTERINE NEOPLASMS;

EID: 0035289626     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.8.2.239     Document Type: Article

References (3)

1. Sasaki H, Ochiai K, Terashima Y, Sato S, Yajima A, Murakami A, Ueda K, Nishimura R, Hascgawa K, Takcuchi K, Tanaka H, Yakushiji M, Watanabc H, Ikeda M and Noda K: Immunohisto-chemical characterization of thymidinc phosphorylasc in gynecologic tumor tissues. J Jpn Soc Cancer Ther 30: 1204, 1995.
2. Ishikawa F, Miyazono K, Mellman U, Drcxler H, Wenstcdt C, Hagiwara K, Usuki K, Takaku F, Risau W and Heldin CH: Identification of angiogenic activity and the cloning and expression of platelet-derived endothclial cell growth factor. Nature 338: 557-562, 1989.
3. Takebayashi Y, Akiyama S, Akiba S, Yamada K, Miyadera K, Sumizawa T, Yamada Y, Murata F and Aikou T: Clinicopathologic and prognostic significance of an angiogenic factor thymidine phosphorylasc, in human colorectal carcinoma. J Natl Cancer Inst 88: 1116-1117, 1996.